Abstract: The invention relates to methods of treating a patient suffering from an IL-33-mediated disorder, such as asthma, comprising administering to the patient an IL-33 axis binding antagonist based on the genotype of the /L1RL1gene, the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2. The invention further relates to methods of determining whether a patient is at increased risk of an IL-33-mediated disorder, as well as methods of determining whether a patient suffering from such a disorder is likely to respond to a treatment comprising an IL-33 axis binding antagonist, based on the genotype of the /L1RL1gene the genotype of a polymorphism in genomic vicinity to the IL-33 gene, the expression level of periostin or the expression level of soluble ST2.

Abstract: The present invention provides a method for testing the DNA of the source of the parasite in a sample, a method for diagnosing, using the testing method, whether a host object is suffered with a parasitic infection, a method for determining a treatment effect on a parasitic infection, and a method for screening a candidate treatment of a parasitic infection. Also provided is a kit for the methods.

Abstract: An object of the present invention is to provide a novel method for designing a primer ensuring reactivity and discriminatory power in a method for detecting a single base substitution based on an ASP-PCR method and to provide a method for easily detecting multiple point mutations within overlapping amplicons, particularly, two adjacent single base substitutions. The single base substitutions can easily be detected by using a mutant primer in which the base of the third nucleotide from the 3? end corresponds to the base of a mutant nucleotide of a single base substitution contained in a nucleic acid sample, in which the base of the second nucleotide from the 3? end is not complementary to the base of the corresponding nucleotide of the nucleic acid, and in which the bases of the other nucleotides are complementary to the bases of the corresponding nucleotides of the nucleic acid.

Abstract: A method to detect ovarian cancer is provided that employs probes and/or primers to detect certain RNA isoform transcripts, as well as kits therefor.

Abstract: Biomarkers for the treatment of pathological conditions associated with the PI3K pathway, such as cancer, and methods of using inhibitors of upstream components of the PI3K pathway, such as PI3K-? inhibitors or AKT inhibitors, are described. In particular, there are described biomarkers for patient selection in the treatment of cancer, as well as methods of therapeutic treatment, diagnostic kits and methods of detection, wherein cancers that possess a mutation in an upstream component of the PI3K pathway (such as the PIK3CA gene and/or the AKT gene), and a wild-type MAP3K1 gene and MAP2K4 gene, are more likely to respond favourably to treatment with inhibitors of upstream components of the PI3K pathway.

Abstract: The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.

Abstract: The present disclosure provides a multiplexed amplification reaction kit for identifying a subject suffering from a malignancy sensitive to treatment with an inhibitor of the Wnt signaling pathway, comprising a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion. Also disclosed is a method of identifying sensitivity to an inhibitor of Wnt signaling in a subject suffering from a malignancy, comprising detecting the PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion with a primer pair.

Abstract: Biomarkers and methods of using them for aiding diagnosis, prognosis, and treatment of critically ill patients are disclosed. In particular, the invention relates to the use of biomarkers for prognosis of mortality in critically ill patients with sepsis, severe trauma, or burns.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.

Abstract: A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

Abstract: Provided in the present invention is a chicken whole-genome SNP chip and application thereof. There are a total of 50,000 SNP loci on the chip: including 19,600 SNP loci for white-feather broilers, yellow-feather and partridge chickens having a MAF value greater than 0.05 and uniformly distributed across the genome which were derived from the data of the whole-genome resequencing of main indigenous chicken breeds in China and introduced chicken breeds; 14,000 SNP loci associated with economic traits, and 16,400 SNP loci for making up for the genomic regions that are not covered by the first two types of probes. The 50,000 SNP loci on the chicken whole-genome SNP chip of the present invention have DNA sequences represented by SEQ ID NOs. 1 to 50,000.

Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.

Abstract: The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

Abstract: The present invention relates to methods and kits for treating cardiovascular disease.

Abstract: Compositions and methods are described that provide prognostic determination of the severity of influenza infection based on the PDE3A status of an individual. Impaired PDE3A function is associated with severe symptoms on contracting influenza. Specific SNP mutations are identified that are associated with impaired PDE3A function, and primers and kits are provided that permit identification of these SNPs. Such information can also be combined with other patient data.

Abstract: The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.

Abstract: The methods described herein include methods for the treatment of subjects who have Clonal Hematopoiesis of Indeterminate Potential (CHIP) or a Philadelphia-negative myeloproliferative neoplasm (MPN), e.g., polycythaemia vera (PV) or essential thrombocythaemia (ET), using inhibitors of JAK-STAT signaling.

Abstract: The present disclosure provides compositions and methods that employ the compositions for conducting pairwise sequencing and for generating concatemer template molecules for pairwise sequencing. The concatemers can be generated using a rolling circle amplification reaction which is conducted either on-support, or conducted in-solution and then distributed onto a support. The rolling circle amplification reaction generates concatemers containing tandem copies of a sequence of interest and at least one universal adaptor sequence. An increase in the number of tandem copies in a given concatemer increases the number of sites along the concatemer for hybridizing to multiple sequencing primers which serve as multiple initiation sites for polymerase-catalyzed sequencing reactions. When the sequencing reaction employs detectably labeled nucleotides and/or detectably labeled multivalent molecules (e.g.

Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.

Abstract: The present invention is directed to methods for detecting a colon cancer, methods for determining whether a colon cancer is stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a colon cancer to a therapy.